Influvac Sub-Unit

Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26) and Influenza A/Vic, the active ingredients in Influvac Sub-Unit, are subunit vaccine components presented as a subunit vaccine for intramuscular or subcutaneous use. They stimulate immunity to prevent influenza infection caused by influenza A and B viruses in children and adults.

GNH USA supplies Influvac Sub-Unit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory support for global immunization programmes.

Influvac Sub-Unit is indicated for active immunization against seasonal influenza caused by influenza A and B viruses.

- Seasonal influenza: reduces the risk of laboratory‑confirmed influenza infection in the general population. - High‑risk groups (elderly, chronic disease patients): provides added protection to lower rates of severe disease and hospitalization. - Pandemic preparedness: contributes to herd immunity and supports public health response to emerging influenza strains.

Influvac Sub-Unit may be associated with local and systemic reactions following administration.

Common Side Effects: - Pain at the injection site: mild to moderate discomfort. - Redness and swelling: transient local inflammation. - Low‑grade fever: usually resolves within 24‑48 hours. - Headache: mild and self‑limiting. - Myalgia: muscle aches that improve spontaneously. - Fatigue: temporary feeling of tiredness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder reported post‑vaccination. - Severe allergic reaction: including angioedema or bronchospasm. - Seizures: uncommon, especially in children with pre‑existing neurological conditions. - High‑grade fever: persistent fever above 39 °C. - Extensive skin rash: widespread erythema or urticaria.

Prior to vaccination, consider the following precautions to ensure safe use of Influvac Sub-Unit.

- Contraindication: known severe allergy to any vaccine component. - Pregnancy: safety not established; weigh benefits against potential risks. - Immunocompromised patients: may have reduced immune response. - Acute illness: defer vaccination until recovery from moderate or severe febrile illness. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Influvac Sub-Unit may interact with other medical products or therapies.

Major Interactions (Avoid): - Concurrent administration of another influenza vaccine: avoid duplicate dosing. - Live attenuated vaccines given within 4 weeks: may interfere with immune response.

Moderate Interactions (Monitor Closely): - Immunosuppressive therapy (e.g., corticosteroids, chemotherapy): may diminish antibody response. - Prophylactic antipyretics: may reduce vaccine‑induced fever but not efficacy. - Blood products administered within 48 hours: may affect immune activation.